Current Report Filing (8-k)
August 16 2017 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
August 15, 2017
Enzo Biochem, Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
New York
|
(State or Other Jurisdiction of Incorporation)
|
|
|
|
001-09974
|
|
13-2866202
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
527 Madison Avenue
|
|
|
New York, New York
|
|
10022
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
(212) 583-0100
|
(Registrant’s Telephone Number, Including Area Code)
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 450 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-1 of this chapter). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01. Other Events.
A federal judge for the U.S. District Court for the District
of Delaware has entered an order in the action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories, denying summary judgment
that U.S. Patent No. 8,097,405 (“the ’405 Patent”) is invalid for lack of written description, but granting summary
judgment that the ’405 Patent is invalid for lack of enablement.
Enzo disagrees with the Court’s decision, and is exploring
options for review of the decision. The Court did not rule on any other pending motions.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ENZO BIOCHEM, INC.
|
|
|
Date: August 16, 2017
|
By:
|
/s/ Barry W. Weiner
|
|
|
|
Barry W. Weiner
|
|
|
|
President
|
|
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Sep 2023 to Sep 2024